Lymphoma & Plasma Cell Disorders
From the Journals
Study challenges LVEF assessment before DLBCL treatment
Preliminary findings have researchers questioning why cardiac testing is routine before administering chemotherapy containing doxorubicin.
News
Study supports sequencing in kids with cancer
SAN DIEGO—Comprehensive next-generation sequencing is both feasible and clinically useful in pediatric cancer patients, a new study suggests....
From the Journals
Ibrutinib discontinuation harms survival in CLL
A single-institution study examines the impact of early dose reduction of ibrutinib in non-Hodgkin lymphoma and CLL.
News
BTK inhibitor shows early promise for WM
NEW YORK—The BTK inhibitor zanubrutinib has demonstrated “robust activity” and “good tolerability” in patients with Waldenström’s...
News
sNDA gets priority review for CLL/SLL
The U.S.
News
Understanding the role of HSCT in PTCL
DUBROVNIK, CROATIA—Hematopoietic stem cell transplant (HSCT) can be hit-or-miss in patients with peripheral T-cell lymphomas (PTCLs), according to...
News
FDA issues draft guidance on MRD
The U.S.
From the Journals
Entospletinib falls short in relapsed/refractory DLBCL
The oral, selective inhibitor of spleen tyrosine kinase had a high rate of adverse events and treatment interruption in the phase 2 study.
Conference Coverage
Updated ThroLy system predicts need for thromboprophylaxis
DUBROVNIK, CROATIA – The revised ThroLy scoring system offers a lymphoma-specific system to predict thromboembolic events.
News
Inhibitor receives orphan designation for PTCL
The U.S.
Conference Coverage
MCL treatment choices depend partly on age
CHICAGO – There are important treatment differences in patients aged 65 and younger versus those over 65.